Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Piperacillin-tazobactam

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section
Search DailyMed products (opens in a new tab)

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Piperacillin Tazo -Zosyn ® (opens in a new tab)Original source URL: https://globalrph.com/dilution/piperacillin-tazo-zosyn/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/piperacillin-tazo-zosyn/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:47:11.261921+00:00
Source location
div.post-content
Packaged content SHA-256
bb2e6e1ad3c7261c9f031fc51408c572d1959253c7cf707fe141ada851f142c5
Original response SHA-256
c3f3365def6467ed79aeade1076a3ee6a5a97212e5590c8a7f8974a7498a84d9
Source body SHA-256
f44441558eab58d302b227a9cb64883d5ee740b9f1d610a744a69b1ec20a20b6

Piperacillin/Tazobactam (Zosyn ®)
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents
D5W, NS

Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate]
Primary:
Use 'Ready-made infusion bags': Zosyn (piperacillin and tazobactam injection) in Galaxy® Container (PL 2040 Plastic) is supplied as a frozen, iso-osmotic, sterile, nonpyrogenic solution in single-dose plastic containersSecondary (If ready-made infusion bags are not available):
Extemporaneous preparation using single dose vials:
[2.25 grams] [50 ml] [30 min]
[3.375 grams] [100 ml] [30 min]
[4.5 grams] [100 ml] [30 min]

Stability / Miscellaneous

Stability data:
Drug Stability
Refrigerated		 Stability
Room Temp.		 Reconstituted
Vial/Powder		 Notes
Zosyn Single dose vial should be used immediately after reconstitution. Discard any unused portion after 24 hours if stored at room temp (20°C to 25°C [68°F to 77°F]),

or after 48 hours if stored at refrigerated temp (2°C to 8°C [36°F to 46°F]). Vials should not be frozen after reconstitution.

 ZOSYN for Injection vials should be stored at controlled room temperature (20°C to 25°C [68°F to 77°F]) prior to reconstitution.

Single dose vial should be used immediately after reconstitution. Discard any unused portion after 24 hours if stored at room temperature (20°C to 25°C [68°F to 77°F]), or after 48 hours if stored at refrigerated temperature (2°C to 8°C [36°F to 46°F]). Vials should not be frozen after reconstitution.

 Powder Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Label: Refrigerate.
Cannot be given IM.

DOSAGE AND ADMINISTRATION
Zosyn should be administered by intravenous infusion over 30 minutes.
The usual daily dose of Zosyn for adults is 3.375 g every six hours.

Nosocomial Pneumonia
Initial presumptive treatment of patients with nosocomial pneumonia should start with Zosyn at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeruginosa is isolated. If Pseudomonas aeruginosa is not isolated, the aminoglycoside may be discontinued at the discretion of the treating physician.

Due to the in vitro inactivation of the aminoglycoside by beta-lactam antibiotics, Zosyn and the aminoglycoside are recommended for separate administration. Zosyn and the aminoglycoside should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated.

Renal Insufficiency
In patients with renal insufficiency (Creatinine Clearance ≤ 40 mL/min), the intravenous dose of Zosyn (piperacillin and tazobactam for injection) should be adjusted to the degree of actual renal function impairment. In patients with nosocomial pneumonia receiving concomitant aminoglycoside therapy, the aminoglycoside dosage should be adjusted according to the recommendations of the manufacturer. The recommended daily doses of Zosyn for patients with renal insufficiency are as follows: Recommended Dosing of Zosyn in Patients with Normal Renal Function and Renal Insufficiency (As total grams piperacillin/tazobactam)

Separate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal FunctionSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
(Creatinine Clearance, mL/min)		 All Indications (except nosocomial pneumonia) Nosocomial Pneumonia
* Creatinine clearance for patients not receiving hemodialysis
** 0.75 g should be administered following each hemodialysis session on hemodialysis days
>40 mL/min 3.375 q 6 h 4.5 q 6 h
20-40 mL/min* 2.25 q 6 h 3.375 q 6 h
<20 mL/min* 2.25 q 8 h 2.25 q 6 h
Hemodialysis**Separate renal reference: Open Renal Dosing Master (opens in a new tab) 2.25 q 12 h 2.25 q 8 h
CAPD 2.25 q 12 h 2.25 q 8 h

For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia. Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g Zosyn should be administered following each dialysis period on hemodialysis days. No additional dosage of Zosyn is necessary for CAPD patients.

Duration of Therapy
The usual duration of Zosyn treatment is from seven to ten days. However, the recommended duration of Zosyn treatment of nosocomial pneumonia is 7 to 14 days. In all conditions, the duration of therapy should be guided by the severity of the infection and the patient's clinical and bacteriological progress.

Directions for Reconstitution and Dilution for Use
Intravenous Administration
Pharmacy Bulk Package
Not for Direct Infusion

RECONSTITUTED STOCK SOLUTION MUST BE TRANSFERRED AND FURTHER DILUTED FOR I.V. INFUSION
The pharmacy bulk vial is for use in a hospital pharmacy admixture service only under a laminar flow hood. After reconstitution, entry into the vial must be made with a sterile transfer set or other sterile dispensing device, and contents should be dispensed as aliquots into intravenous solution using aseptic technique. Use entire contents of pharmacy bulk vial promptly. Discard unused portion after 24 hours if stored at room temperature (20°C to 25°C [68°F to 77°F]), or after 48 hours if stored at refrigerated temperature (2°C to 8°C [36°F to 46°F]).

Reconstitute the pharmacy bulk vial with exactly 152 mL of a compatible reconstitution diluent, listed below, to a concentration of 200 mg/mL of piperacillin and 25 mg/mL of tazobactam. Shake well until dissolved. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.

Compatible Reconstitution Diluents
0.9% Sodium Chloride for Injection
Sterile Water for Injection‡
Dextrose 5%
Bacteriostatic Saline/Parabens
Bacteriostatic Water/Parabens
Bacteriostatic Saline/Benzyl Alcohol
Bacteriostatic Water/Benzyl Alcohol

Reconstituted Zosyn solution should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below. Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution.

Compatible Intravenous Solutions
0.9% Sodium Chloride for Injection
Sterile Water for Injection‡
Dextran 6% in Saline
Dextrose 5%
Lactated Ringer's Solution (Compatible only with reformulated Zosyn containing EDTA)

‡Maximum recommended volume per dose of Sterile Water for Injection is 50 mL.

Zosyn should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.

Zosyn is not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH.

Zosyn should not be added to blood products or albumin hydrolysates.

Zosyn can be used in ambulatory intravenous infusion pumps.

Stability of Zosyn Following Reconstitution
Zosyn is stable in glass and plastic containers (plastic syringes, I.V. bags and tubing) when used with compatible diluents.

The pharmacy bulk vial should NOT be frozen after reconstitution. Discard unused portions after storage for 24 hours at room temperature or after storage for 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]).

Stability studies in the I.V. bags have demonstrated chemical stability [potency, pH of reconstituted solution, and clarity of solution] for up to 24 hours at room temperature and up to one week at refrigerated temperature. Zosyn contains no preservatives. Appropriate consideration of aseptic technique should be used.

Stability of Zosyn (piperacillin and tazobactam for injection) in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature. Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL. One-day supplies of dosing solution were aseptically transferred into the medication reservoir (I.V. bags or cartridge). The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions. Stability of Zosyn is not affected when administered using an ambulatory intravenous infusion pump.

Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED
Zosyn® (piperacillin and tazobactam for injection) is supplied as a powder in the pharmacy bulk vial as follows:

Each Zosyn 40.5 g pharmacy bulk vial contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams tazobactam, 9 mg of edetate disodium dihydrate (EDTA) and 1800 mg of sodium citrate. Each pharmacy bulk vial contains 100.4 mEq (2,304 mg) of sodium.
NDC 0206-8859-10

Zosyn (piperacillin and tazobactam for injection) pharmacy bulk vials should be stored at controlled room temperature 20°C to 25°C (68°F to 77°F) prior to reconstitution.

Also Available
Zosyn (piperacillin and tazobactam for injection) is also supplied as follows:

2.25 g single-dose vial containing piperacillin sodium equivalent to 2 g of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam. Each vial contains 5.58 mEq (128 mg) of sodium. Supplied 10/box-NDC 0206-8852-16

3.375 g single-dose vial containing piperacillin sodium equivalent to 3 g of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam. Each vial contains 8.38 mEq (192 mg) of sodium. Supplied 10/box-NDC 0206-8854-16

4.5 g single-dose vial containing piperacillin sodium equivalent to 4 g of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam. Each vial contains 11.17 mEq (256 mg) of sodium. Supplied 10/box-NDC 0206-8855-16

Zosyn (piperacillin and tazobactam for injection) is also supplied in the ADD-Vantage® Vial as follows:

2.25 g ADD-Vantage® vial (piperacillin sodium equivalent to 2 g piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam). Each ADD-Vantage® vial contains 5.58 mEq (128 mg) of sodium. Supplied 10/box-NDC 0206-8852-18

3.375 g ADD-Vantage® vial (piperacillin sodium equivalent to 3 g piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam). Each ADD-Vantage® vial contains 8.38 mEq (192 mg) of sodium. Supplied 10/box-NDC 0206-8854-18

4.5 g ADD-Vantage® vial (piperacillin sodium equivalent to 4 g piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam). Each ADD-Vantage® vial contains 11.17 mEq (256 mg) of sodium. Supplied 10/box-NDC 0206-8855-18

Also Available
Zosyn (piperacillin and tazobactam injection) in Galaxy® Container (PL 2040 Plastic) is supplied as a frozen, iso-osmotic, sterile, nonpyrogenic solution in single-dose plastic containers as follows:

2.25 g (piperacillin sodium equivalent to 2 g piperacillin/tazobactam sodium equivalent to 0.25 g tazobactam) in 50 mL. Each container has 5.58 mEq (128 mg) of sodium. Supplied 24/box-NDC 0206-8860-02

3.375 g (piperacillin sodium equivalent to 3 g piperacillin/tazobactam sodium equivalent to 0.375 g tazobactam) in 50 mL. Each container has 8.38 mEq (192 mg) of sodium. Supplied 24/box-NDC 0206-8861-02

4.5 g (piperacillin sodium equivalent to 4 g piperacillin/tazobactam sodium equivalent to 0.5 g tazobactam) in 100 mL. Each container has 11.17 mEq (256 mg) of sodium. Supplied 12/box-NDC 0206-8862-02

CLINITEST® and DIASTIX® are registered trademarks of Ames Division, Miles Laboratories, Inc.
TES-TAPE® is a registered trademark of Eli Lilly and Company.
Galaxy® is a registered trademark of Baxter International, Inc.
ADD-Vantage® is a registered trademark of Abbott Laboratories.

Wyeth®
Wyeth Pharmaceuticals Inc.
Philadelphia, PA 19101
W10416C010
ET01
Rev 02/07

Source: [package insert]

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
adjustment_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        class_level
        Provenance classification
        historical_class_level
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      piperacillin-tazobactam
      Source IDH51-B095BA9B18129F5C5B450080
      Generic name
      Piperacillin-tazobactam
      Source IDH51-A1D6B0387FAF3B164B0508CF
      Class
      Antibacterial
      Source IDH51-A8E3A46FC1ACB2AB387989C3
      Subclass
      Extended-spectrum penicillin plus beta-lactamase inhibitor
      Source IDH51-7DB177F3FB71C556FC0AE3FA
      Primary uses
      1. Severe polymicrobial infection
        Source IDH51-38F51EA27340B6EDEABDD886
      2. Hospital-acquired pneumonia
        Source IDH51-BA0BBDEE3EF271E4B7B7DE13
      3. Intra-abdominal infection
        Source IDH51-2A29B99F35B5E2C60B709C50
      Mechanism
      The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms.
      Source IDH51-28E40107F080D668113ED3F4
      Mechanism level
      class_level
      Source IDH51-DFC6AC6AB50A54CF62CDC7EB
      Basic dosing orientation
      Adult | Existing preparation record; use current package insert for indication-specific selection | Common product dose 3.375 or 4.5 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric | Existing preparation record; use current package insert for indication-specific selection | Dose often expressed by piperacillin component; verify convention | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion
      Source IDH51-FC6E8BDEA528BB76FBF5D6AC
      Administration orientation
      Standard infusion over 30 minutes or validated extended infusion over 3 to 4 hours; Infuse over 30 minutes or validated extended infusion
      Source IDH51-46C3F9EBA7B45F4B2F4BB58A
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-4FB3B45478CE882A20AA1785
      Key safety orientation
      1. Renal adjustment is required.
        Source IDH51-91CE61AA0B1245ADAB79C3AD
      2. Substantial sodium load may matter in fluid-sensitive patients.
        Source IDH51-9195D85AEA19E24C7FBAFA37
      3. Dose-expression errors are possible.
        Source IDH51-EBDFA33ECC320ED4B0C328D4
      Coverage path
      structured_local_snapshot
      Source IDH51-0C49E2FBA08EFCE36C44D69A
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-5D81BC8627EAB0CC4B4F2978
      Legacy title
      Piperacillin-tazobactam
      Source IDH51-7298CD969A1E6318FAE5F55C
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-8409B0A4DF8E45333C7A9A96
      Search text
      Piperacillin-tazobactam Antibacterial Extended-spectrum penicillin plus beta-lactamase inhibitor Severe polymicrobial infection Hospital-acquired pneumonia Intra-abdominal infection The beta-lactam component inhibits penicillin-binding proteins and cell-wall synthesis; its partner protects or enhances activity against selected resistance mechanisms. Adult | Existing preparation record; use current package insert for indication-specific selection | Common product dose 3.375 or 4.5 g | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Pediatric | Existing preparation record; use current package insert for indication-specific selection | Dose often expressed by piperacillin component; verify convention | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion Standard infusion over 30 minutes or validated extended infusion over 3 to 4 hours; Infuse over 30 minutes or validated extended infusion Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method. Renal adjustment is required. Substantial sodium load may matter in fluid-sensitive patients. Dose-expression errors are possible. Structured GlobalRPh route snapshot
      Source IDH51-7F752E00A215538CA746C70E
      Official access mode
      search
      Source IDH51-717348EEBA6F8918DBCE17C1
      Official search query
      Piperacillin-tazobactam
      Source IDH51-DD25FBF12B51F9966DD91867
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-C7DA6E32E9FB0D731F0147F7

      No separate structured rows were bundled for IV push, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical dilution and intermittent infusion preparation

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationAmountReconstitutionDiluentFinal volumeConcentrationRateStabilityNotes
      Source IDH51-273E599428D8DB169D707014
      Adult
      Source IDH51-72C560A6407620B31827A4DF
      		Common product dose 3.375 or 4.5 g
      Source IDH51-C3C4782F22418A29453207CF
      		Reconstitute vial with label-compatible diluent.
      Source IDH51-EC89EE4D6AEE138BE8EBD6B5
      		NS or D5W
      Source IDH51-25C21CA84081069AA96F6B4D
      		50 to 100 mL
      Source IDH51-7D339B3CF79B19C9EB0DF9FC
      		Commonly 33.75 to 90 mg/mL total product
      Source IDH51-C3425C110FBB9B1ED2DB54CB
      		Standard infusion over 30 minutes or validated extended infusion over 3 to 4 hours
      Source IDH51-A26323ACEDB3D8A8775E5727
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-C91C10E65F107E96502F8F75
      		Extended infusion schedules are institution-specific and require stability validation.
      Source IDH51-63ECDDAFDBDF876861CE34FF
      Source IDH51-A87D0DCF79AD869C525BA08E
      Pediatric
      Source IDH51-4859D869C94ED7C236343EBD
      		Dose often expressed by piperacillin component; verify convention
      Source IDH51-B3386A2EA924D32B4996746E
      		Reconstitute per vial labeling.
      Source IDH51-2FD50E249080D2D83845C2AB
      		Compatible fluid
      Source IDH51-83F836459D02AE82222CFA9E
      		Weight-appropriate volume
      Source IDH51-09AAFEBE3F0FD75379B2CEA9
      		Institution-specific
      Source IDH51-932617495F0013FBFEC7BC98
      		Infuse over 30 minutes or validated extended infusion
      Source IDH51-1A2C3A7C8DC9F2C8CF2A2601
      		Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.
      Source IDH51-DBAFEEA80ACDCE286BF12289
      		Always label whether dose is piperacillin component or total product.
      Source IDH51-93B75F0EC4260F0845CBA5DC

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-E7F42A31EC961CB4D90393E8
      IV infusion
      Source IDH51-7A6F596C47B1B15CD4FF4A47
      		Adult
      Source IDH51-CAA282F11694FBDB8BC848AF
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-8FE98EE40E5304415772539F
      		Common product dose 3.375 or 4.5 g
      Source IDH51-2525F6E089438F796D01492E
      		Not normalized in the preparation record
      Source IDH51-3EEA778900A4A782C48D9683
      		See current package insert and professional guidance
      Source IDH51-FDCA4A2CDA5F5BFE5131BF03
      		Standard infusion over 30 minutes or validated extended infusion over 3 to 4 hours
      Source IDH51-60AB426BC37411BDEE90B70E
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-E5B63F526B8C7BAC9F91DB3C
      		Extended infusion schedules are institution-specific and require stability validation.
      Source IDH51-E32508EBA89207A053CAE583
      Source IDH51-7380109535AFC7D980E697D6
      IV infusion
      Source IDH51-05D88E578DBE40332FA352F8
      		Pediatric
      Source IDH51-B413A8431294752A6B379F81
      		Existing preparation record; use current package insert for indication-specific selection
      Source IDH51-BFA0E6B7BEA13D5C17E4DDB2
      		Dose often expressed by piperacillin component; verify convention
      Source IDH51-6B18B9DAE1A3C1DB06BEB658
      		Not normalized in the preparation record
      Source IDH51-4B787DDFEF83CA3E242497DE
      		See current package insert and professional guidance
      Source IDH51-F8B09122F31C9519C23697E5
      		Infuse over 30 minutes or validated extended infusion
      Source IDH51-BC2C61670A615D5902445AAE
      		Existing GlobalRPh structured preparation snapshot
      Source IDH51-F7D32E692E912B74D1D161C7
      		Always label whether dose is piperacillin component or total product.
      Source IDH51-B600B59BA0DF2C942F37590D

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      adjustment_required
      Source IDH51-0FF6C28776C9B53B4FB82AB7
      Summary
      Renal dose adjustment or interval modification is commonly required; verify the selected product label and patient-specific renal method.
      Source IDH51-7F30153B8B1061455F296263
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-20356D626AE7BCDC8E7B4F9A

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Severe polymicrobial infection
        Source IDH51-5F1D348BA61E3871E9B8611D
      2. Hospital-acquired pneumonia
        Source IDH51-38406CA29FF6A49713DFCBEB
      3. Intra-abdominal infection
        Source IDH51-96A4A8DAE6330A13BED72F3E

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Renal adjustment is required.
        Source IDH51-410345D91136D4D3E7E5A604
      2. Substantial sodium load may matter in fluid-sensitive patients.
        Source IDH51-6A85C5118F1D4337C355BFAE
      3. Dose-expression errors are possible.
        Source IDH51-2E8A824EFE1337E19EA6FF01

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      1. Renal function
        Source IDH51-D61B1222E3D9A33E23461660
      2. Electrolytes and sodium burden
        Source IDH51-24EBFED35A09AE6CDBD2D7DF
      3. CBC and hepatic tests during prolonged therapy
        Source IDH51-A7C769B4EDDB7C39F5533681

      Historical supplemental professional sources

      Recovered v5.1 source content; historical, awaiting current review.

      LabelUrlKind
      Source IDH51-EB60DBF5916B88440D9646C6
      UCSF adult antimicrobial dosing, non-dialysis
      Source IDH51-6C7BEFA82255ACD8199704CB
      		https://idmp.ucsf.edu/adult-antimicrobial-dosing-non-dialysis (opens in a new tab)
      Source IDH51-608288924B8DD817AF05096B
      		Professional institutional guidance
      Source IDH51-D760C0EBDDF5DEF7955FEB64
      Source IDH51-0C53000B29209CCCE5200DB2
      UCSF antimicrobial dosing in intermittent and continuous hemodialysis
      Source IDH51-BC91D4FA5F4B3510C6296593
      		https://idmp.ucsf.edu/antimicrobial-dosing-intermittent-continuous-hemodialysis (opens in a new tab)
      Source IDH51-53B2BF6044E429DF597674C7
      		Professional institutional guidance
      Source IDH51-3451E9EDF2C21A74FC5FAC9E
      Source IDH51-94E082E10E8BF0B4BB0B2647
      UCSF pediatric antimicrobial dosing
      Source IDH51-7FBF1294671B4D58AAAFC9F6
      		https://idmp.ucsf.edu/pediatric-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-242E528F3A7C2BFFC629E054
      		Professional institutional guidance
      Source IDH51-24E23F7A442334EE846C1FBD
      Source IDH51-0C44567F39D19D1E7C1D1AFE
      UCSF neonatal antimicrobial dosing
      Source IDH51-086DFF249D815EA50F60D27E
      		https://idmp.ucsf.edu/neonatal-antimicrobial-dosing-benioff-childrens-hospitals (opens in a new tab)
      Source IDH51-DAAA3C7A67A53C65B9F238B2
      		Professional institutional guidance
      Source IDH51-D9CAC965674236D75860803A
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      piperacillin-tazobactam
      Source IDH51-F04A21BB29598C916B6C8198
      Generic name
      Piperacillin-tazobactam
      Source IDH51-0B3CE13A426B2FF76A00302D
      Brand names
      1. Zosyn
        Source IDH51-E20EB025EE5DF04E67A74244
      Aliases
      1. pip-tazo
        Source IDH51-B799AE283879BB34BFFAE5EB
      Class
      Antibacterial
      Source IDH51-940EC622AD2B94E0375D78FE
      Subclass
      Extended-spectrum penicillin plus beta-lactamase inhibitor
      Source IDH51-A5AA35BBAE7938A0DC031593
      Summary
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Fixed 8:1 piperacillin-to-tazobactam combination used by standard or extended infusion; dose expression and renal adjustment must be explicit.
      Source IDH51-8BB189FC2CF3DFB06C3B96BB
      Populations
      1. Adult
        Source IDH51-5F44AD5BAE750FE450D95F82
      2. Pediatric
        Source IDH51-EBF05911A711F69B7A9BF00A
      Evidence tier
      Core reference - verify current label
      Source IDH51-8510A1154E24511759CA5D0A
      High alert
      true
      Source IDH51-486D17090BF20D7035BA0EF6
      Hazardous
      false
      Source IDH51-A7795C854557CB5CAF3954A7
      Status
      Active
      Source IDH51-F4C39EE1479320A7D15B1CFB
      Reviewed
      2026-08-29
      Source IDH51-6FD5C5A93B3525521E91E903
      Version added
      1.0
      Source IDH51-EA5E41FF76399C448B6ED96B
      Sources
      LabelUrlKind
      Source IDH51-E2440AD15D414913C35EC9E2
      DailyMed label search
      Source IDH51-92E03CCCC265FA583B370ACF
      		https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Piperacillin-tazobactam (opens in a new tab)
      Source IDH51-8EE6AEFFD1C82240639E2ACA
      		Primary
      Source IDH51-0935050E35356BD4A5949088
      Source IDH51-9275A900CD8767D09002CB45
      GlobalRPh legacy IV dilution monograph
      Source IDH51-12F5A9FBE599589735633FFC
      		legacy:auto
      Source IDH51-58C19FF56C292A402993D146
      		Legacy
      Source IDH51-A5EAAFE44F4875574440E976
      Legacy title
      Piperacillin-tazobactam
      Source IDH51-D07EE1EA9260AEFDFBF528B2
      Clinical release verification
      Audit version
      3.4
      Source IDH51-17861643BD28B3D73DD7754A
      Audited on
      2026-08-30
      Source IDH51-86B3A6AB14AF8CE8DADC3D88
      Level
      amber
      Source IDH51-56A8302D9F79A714A10DCF50
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-0F78BC183971F9BD272D9A58
      Exact current label candidate
      false
      Source IDH51-E76F7E7E92D77867E2AB5643
      Numeric support ratio
      0
      Source IDH51-1C8E5059CB2A4729BFF416BF
      Reference url count
      5
      Source IDH51-05AEA3647CD4A617C8B3905A
      Broken reference count
      0
      Source IDH51-394AB9A479850D4A430CF809
      Point of use confirmation required
      true
      Source IDH51-27BD2BA6E76908807E4E5A0C
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-6D6418E478F4F27D829288FA

      Dosing source fields

      Id
      piperacillin-tazobactam
      Source IDH51-EB623CF0860E394AD7CE3D55
      Generic name
      Piperacillin-tazobactam
      Source IDH51-378B755D0194C8061FA57600
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-28EC3A322FFDBE5CBB5CEF64
      Package insert
      Query name
      Piperacillin-tazobactam
      Source IDH51-01F463DCCE3996B1BDDCBBC3
      Product and route must match
      true
      Source IDH51-4084F93FD9CBC59A3585A9DC
      Live current label enabled
      false
      Source IDH51-A4F3491C46CCB27BC5DA266B
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-F8DD13F2592DC25B68EC6A4D
      Direct official label access enabled
      true
      Source IDH51-0D29ADA319CC840867334963
      Outbound server request required
      false
      Source IDH51-377813059F4638516A24137B
      Local summary status
      not_bundled
      Source IDH51-77CFFE93B44840DB4DF668E1
      Clinical review
      Locally normalized
      false
      Source IDH51-8BFD25FF74962165FF61002F
      Reviewed
      2026-08-29
      Source IDH51-D188EBAEAF2921A0F78B99B8
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-F882C21AAC8AF314A3D7EBFB
      Clinical release verification
      Audit version
      3.4
      Source IDH51-05234B26C4CD286F4B9D1372
      Audited on
      2026-08-30
      Source IDH51-93D106C9DC5FCB93D0C3892C
      Level
      amber
      Source IDH51-A25B6D729C5DE02E956D514C
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-9213DED6D97851B4A9122FA0
      Exact current label candidate
      false
      Source IDH51-367A3EF6A89F6AED3846D892
      Numeric support ratio
      0
      Source IDH51-D0D9D46DF8E4F7D4A36153D9
      Reference url count
      5
      Source IDH51-C41EDE7A3947E159931F4EC0
      Broken reference count
      0
      Source IDH51-DC2774AE2D14710E02FEABFF
      Point of use confirmation required
      true
      Source IDH51-102743B1140E8017CE4A99C1
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-4E199435D3F68EB129FD23DE
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      piperacillin-tazobactam
      Source IDH51-DEEC281C7160897030AC1AEF
      Name
      Piperacillin-tazobactam
      Source IDH51-C203603D6433F83DDA8FEE51
      Brands
      Zosyn
      Source IDH51-82E70676F48A3B834B9C3C72
      Therapeutic class
      Antibacterial
      Source IDH51-B9D6B352917565E090983892
      Review version
      3.1
      Source IDH51-5FF3B9238B512D053941713C
      Review date
      2026-08-30
      Source IDH51-673FE7B91E4BF69B3B071CB2
      Release status
      structured_record_current_label_not_confirmed
      Source IDH51-91D59E8D0E76E4BF5F875256
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-713506B5F9E5ADA6DA9985C9
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-158C382206177259E39E64E5
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-B552748F5D134F26497B388E
      Reconstitution concentration
      Reconstitute vial with label-compatible diluent. Reconstitute per vial labeling.
      Source IDH51-5A52488F05501AF4E032CD94
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-212A06400CB87D4FDF5A50AF
      Appropriate standardized containers
      50 to 100 mL Weight-appropriate volume
      Source IDH51-6F7E9B2B14504B518E03F8EB
      Adult dosing range
      Common product dose 3.375 or 4.5 g Dose often expressed by piperacillin component; verify convention
      Source IDH51-C6D1A8DA64B502E77AEFA365
      Pediatric dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-6943411CCA68506EC47B9767
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-D31DD69873AE432C57BC4467
      Infusion time
      Standard infusion over 30 minutes or validated extended infusion over 3 to 4 hours Infuse over 30 minutes or validated extended infusion
      Source IDH51-EB7D7C78F0EB34A24369C904
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-DD37F61088C9978DC02CE374
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-4D6A670B5A5D7F73B959EBBB
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-E97193D74B3C197E0DBBD707
      Reconstitution concentration
      Primary
      existing_structured_record
      Source IDH51-4E807D8F7D3B33E2D793532A
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-BB28691AF8F07788E30FEF40
      Appropriate standardized containers
      Primary
      existing_structured_record
      Source IDH51-E171D67C3D7298DB50B2E098
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-26FF3EE771068D41C326A4C9
      Pediatric dosing range
      Primary
      not_found
      Source IDH51-DA3035E4814CCEB310EDA68C
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-9D66A2A9ED287F40C209AC44
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-1A405702F2A7F445AADD084F
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-538E73A861332F4DD1396FED
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-7A93B4AF8E6EE5E0749C7462
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-1C5BF4648170E29C17D23D37
      Guide generation allowed
      true
      Source IDH51-DB758937436487AEB8D62C7D
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-85F12B5A5342BE99314342E3
      Guide generation allowed
      false
      Source IDH51-DE267E83D7364E0B9937D7FA
      Neonatal
      Applicability
      supported_or_source_present
      Source IDH51-6DF2C155FC2ABF8EC5E99FA5
      Guide generation allowed
      false
      Source IDH51-5BA0FF8A8044FE43E109EBA5
      Route presence
      Structured dilution
      true
      Source IDH51-C9390843A107B69E7D6614B2
      Iv push
      false
      Source IDH51-9B7E46042133C1CBE3463E37
      Continuous infusion
      false
      Source IDH51-997F222CB875CFC3985B0FAD
      Pediatric source
      true
      Source IDH51-2E645A21B287F676AA2CF1A0
      Neonatal source
      true
      Source IDH51-B82FEB489D61A9C3A8B979A7
      Legacy reference
      Status
      not_available
      Source IDH51-343EA203CFD6F75F72172772
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-AFDEDF348F30DE28336CA4C1
      Source files
      1. catalog.json
        Source IDH51-B9F792D9953F80B010E723DA
      2. dosing.json
        Source IDH51-F444C9C5F45450E3C5A56C11
      3. legacy-map.json
        Source IDH51-BE0FFC1D3D14C4E8878C064D
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-82789C89FA13F192F35D929E
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-F04A21BB29598C916B6C8198catalog.json
      /records/200/id      		Historical; current review incomplete
      H51-0B3CE13A426B2FF76A00302Dcatalog.json
      /records/200/generic_name      		Historical; current review incomplete
      H51-E20EB025EE5DF04E67A74244catalog.json
      /records/200/brand_names/0      		Historical; current review incomplete
      H51-B799AE283879BB34BFFAE5EBcatalog.json
      /records/200/aliases/0      		Historical; current review incomplete
      H51-940EC622AD2B94E0375D78FEcatalog.json
      /records/200/class      		Historical; current review incomplete
      H51-A5AA35BBAE7938A0DC031593catalog.json
      /records/200/subclass      		Historical; current review incomplete
      H51-8BB189FC2CF3DFB06C3B96BBcatalog.json
      /records/200/summary      		Historical; current review incomplete
      H51-5F1D348BA61E3871E9B8611Dcatalog.json
      /records/200/common_uses/0      		Historical; current review incomplete
      H51-38406CA29FF6A49713DFCBEBcatalog.json
      /records/200/common_uses/1      		Historical; current review incomplete
      H51-96A4A8DAE6330A13BED72F3Ecatalog.json
      /records/200/common_uses/2      		Historical; current review incomplete
      H51-273E599428D8DB169D707014catalog.json
      /records/200/preparations/0      		Historical; current review incomplete
      H51-72C560A6407620B31827A4DFcatalog.json
      /records/200/preparations/0/population      		Historical; current review incomplete
      H51-C3C4782F22418A29453207CFcatalog.json
      /records/200/preparations/0/amount      		Historical; current review incomplete
      H51-EC89EE4D6AEE138BE8EBD6B5catalog.json
      /records/200/preparations/0/reconstitution      		Historical; current review incomplete
      H51-25C21CA84081069AA96F6B4Dcatalog.json
      /records/200/preparations/0/diluent      		Historical; current review incomplete
      H51-7D339B3CF79B19C9EB0DF9FCcatalog.json
      /records/200/preparations/0/final_volume      		Historical; current review incomplete
      H51-C3425C110FBB9B1ED2DB54CBcatalog.json
      /records/200/preparations/0/concentration      		Historical; current review incomplete
      H51-A26323ACEDB3D8A8775E5727catalog.json
      /records/200/preparations/0/rate      		Historical; current review incomplete
      H51-C91C10E65F107E96502F8F75catalog.json
      /records/200/preparations/0/stability      		Historical; current review incomplete
      H51-63ECDDAFDBDF876861CE34FFcatalog.json
      /records/200/preparations/0/notes      		Historical; current review incomplete
      H51-A87D0DCF79AD869C525BA08Ecatalog.json
      /records/200/preparations/1      		Historical; current review incomplete
      H51-4859D869C94ED7C236343EBDcatalog.json
      /records/200/preparations/1/population      		Historical; current review incomplete
      H51-B3386A2EA924D32B4996746Ecatalog.json
      /records/200/preparations/1/amount      		Historical; current review incomplete
      H51-2FD50E249080D2D83845C2ABcatalog.json
      /records/200/preparations/1/reconstitution      		Historical; current review incomplete
      H51-83F836459D02AE82222CFA9Ecatalog.json
      /records/200/preparations/1/diluent      		Historical; current review incomplete
      H51-09AAFEBE3F0FD75379B2CEA9catalog.json
      /records/200/preparations/1/final_volume      		Historical; current review incomplete
      H51-932617495F0013FBFEC7BC98catalog.json
      /records/200/preparations/1/concentration      		Historical; current review incomplete
      H51-1A2C3A7C8DC9F2C8CF2A2601catalog.json
      /records/200/preparations/1/rate      		Historical; current review incomplete
      H51-DBAFEEA80ACDCE286BF12289catalog.json
      /records/200/preparations/1/stability      		Historical; current review incomplete
      H51-93B75F0EC4260F0845CBA5DCcatalog.json
      /records/200/preparations/1/notes      		Historical; current review incomplete
      H51-410345D91136D4D3E7E5A604catalog.json
      /records/200/warnings/0      		Historical; current review incomplete
      H51-6A85C5118F1D4337C355BFAEcatalog.json
      /records/200/warnings/1      		Historical; current review incomplete
      H51-2E8A824EFE1337E19EA6FF01catalog.json
      /records/200/warnings/2      		Historical; current review incomplete
      H51-D61B1222E3D9A33E23461660catalog.json
      /records/200/monitoring/0      		Historical; current review incomplete
      H51-24EBFED35A09AE6CDBD2D7DFcatalog.json
      /records/200/monitoring/1      		Historical; current review incomplete
      H51-A7C769B4EDDB7C39F5533681catalog.json
      /records/200/monitoring/2      		Historical; current review incomplete
      H51-5F44AD5BAE750FE450D95F82catalog.json
      /records/200/populations/0      		Historical; current review incomplete
      H51-EBF05911A711F69B7A9BF00Acatalog.json
      /records/200/populations/1      		Historical; current review incomplete
      H51-8510A1154E24511759CA5D0Acatalog.json
      /records/200/evidence_tier      		Historical; current review incomplete
      H51-486D17090BF20D7035BA0EF6catalog.json
      /records/200/high_alert      		Historical; current review incomplete
      H51-A7795C854557CB5CAF3954A7catalog.json
      /records/200/hazardous      		Historical; current review incomplete
      H51-F4C39EE1479320A7D15B1CFBcatalog.json
      /records/200/status      		Historical; current review incomplete
      H51-6FD5C5A93B3525521E91E903catalog.json
      /records/200/reviewed      		Historical; current review incomplete
      H51-EA5E41FF76399C448B6ED96Bcatalog.json
      /records/200/version_added      		Historical; current review incomplete
      H51-E2440AD15D414913C35EC9E2catalog.json
      /records/200/sources/0      		Historical; current review incomplete
      H51-92E03CCCC265FA583B370ACFcatalog.json
      /records/200/sources/0/label      		Historical; current review incomplete
      H51-8EE6AEFFD1C82240639E2ACAcatalog.json
      /records/200/sources/0/url      		Historical; current review incomplete
      H51-0935050E35356BD4A5949088catalog.json
      /records/200/sources/0/kind      		Historical; current review incomplete
      H51-9275A900CD8767D09002CB45catalog.json
      /records/200/sources/1      		Historical; current review incomplete
      H51-12F5A9FBE599589735633FFCcatalog.json
      /records/200/sources/1/label      		Historical; current review incomplete
      H51-58C19FF56C292A402993D146catalog.json
      /records/200/sources/1/url      		Historical; current review incomplete
      H51-A5EAAFE44F4875574440E976catalog.json
      /records/200/sources/1/kind      		Historical; current review incomplete
      H51-D07EE1EA9260AEFDFBF528B2catalog.json
      /records/200/legacy_title      		Historical; current review incomplete
      H51-17861643BD28B3D73DD7754Acatalog.json
      /records/200/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-86B3A6AB14AF8CE8DADC3D88catalog.json
      /records/200/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-56A8302D9F79A714A10DCF50catalog.json
      /records/200/clinical_release_verification/level      		Historical; current review incomplete
      H51-0F78BC183971F9BD272D9A58catalog.json
      /records/200/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-E76F7E7E92D77867E2AB5643catalog.json
      /records/200/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-9B04299A62B424A7973DD15Bcatalog.json
      /records/200/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-80772288D6D373D5AE3BEF00catalog.json
      /records/200/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-1C8E5059CB2A4729BFF416BFcatalog.json
      /records/200/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-05AEA3647CD4A617C8B3905Acatalog.json
      /records/200/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-394AB9A479850D4A430CF809catalog.json
      /records/200/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-27BD2BA6E76908807E4E5A0Ccatalog.json
      /records/200/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-6D6418E478F4F27D829288FAcatalog.json
      /records/200/clinical_release_verification/note      		Historical; current review incomplete
      H51-0C1F4A1B9AE291C2ACBBEF1Acatalog.json
      /records/200/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-EB623CF0860E394AD7CE3D55dosing.json
      /records/200/id      		Historical; current review incomplete
      H51-378B755D0194C8061FA57600dosing.json
      /records/200/generic_name      		Historical; current review incomplete
      H51-28EC3A322FFDBE5CBB5CEF64dosing.json
      /records/200/coverage_status      		Historical; current review incomplete
      H51-01F463DCCE3996B1BDDCBBC3dosing.json
      /records/200/package_insert/query_name      		Historical; current review incomplete
      H51-A282A088A39C140BBF320814dosing.json
      /records/200/package_insert/preferred_setid      		Historical; current review incomplete
      H51-4084F93FD9CBC59A3585A9DCdosing.json
      /records/200/package_insert/product_and_route_must_match      		Historical; current review incomplete
      H51-A4F3491C46CCB27BC5DA266Bdosing.json
      /records/200/package_insert/live_current_label_enabled      		Historical; current review incomplete
      H51-F8DD13F2592DC25B68EC6A4Ddosing.json
      /records/200/package_insert/source_priority      		Historical; current review incomplete
      H51-0D29ADA319CC840867334963dosing.json
      /records/200/package_insert/direct_official_label_access_enabled      		Historical; current review incomplete
      H51-377813059F4638516A24137Bdosing.json
      /records/200/package_insert/outbound_server_request_required      		Historical; current review incomplete
      H51-77CFFE93B44840DB4DF668E1dosing.json
      /records/200/package_insert/local_summary_status      		Historical; current review incomplete
      H51-0FF6C28776C9B53B4FB82AB7dosing.json
      /records/200/renal/classification      		Historical; current review incomplete
      H51-7F30153B8B1061455F296263dosing.json
      /records/200/renal/summary      		Historical; current review incomplete
      H51-20356D626AE7BCDC8E7B4F9Adosing.json
      /records/200/renal/method_note      		Historical; current review incomplete
      H51-E7F42A31EC961CB4D90393E8dosing.json
      /records/200/existing_route_snapshots/0      		Historical; current review incomplete
      H51-7A6F596C47B1B15CD4FF4A47dosing.json
      /records/200/existing_route_snapshots/0/route      		Historical; current review incomplete
      H51-CAA282F11694FBDB8BC848AFdosing.json
      /records/200/existing_route_snapshots/0/population      		Historical; current review incomplete
      H51-8FE98EE40E5304415772539Fdosing.json
      /records/200/existing_route_snapshots/0/indication      		Historical; current review incomplete
      H51-2525F6E089438F796D01492Edosing.json
      /records/200/existing_route_snapshots/0/dose      		Historical; current review incomplete
      H51-3EEA778900A4A782C48D9683dosing.json
      /records/200/existing_route_snapshots/0/interval      		Historical; current review incomplete
      H51-FDCA4A2CDA5F5BFE5131BF03dosing.json
      /records/200/existing_route_snapshots/0/duration      		Historical; current review incomplete
      H51-60AB426BC37411BDEE90B70Edosing.json
      /records/200/existing_route_snapshots/0/administration      		Historical; current review incomplete
      H51-E5B63F526B8C7BAC9F91DB3Cdosing.json
      /records/200/existing_route_snapshots/0/source_level      		Historical; current review incomplete
      H51-E32508EBA89207A053CAE583dosing.json
      /records/200/existing_route_snapshots/0/notes      		Historical; current review incomplete
      H51-7380109535AFC7D980E697D6dosing.json
      /records/200/existing_route_snapshots/1      		Historical; current review incomplete
      H51-05D88E578DBE40332FA352F8dosing.json
      /records/200/existing_route_snapshots/1/route      		Historical; current review incomplete
      H51-B413A8431294752A6B379F81dosing.json
      /records/200/existing_route_snapshots/1/population      		Historical; current review incomplete
      H51-BFA0E6B7BEA13D5C17E4DDB2dosing.json
      /records/200/existing_route_snapshots/1/indication      		Historical; current review incomplete
      H51-6B18B9DAE1A3C1DB06BEB658dosing.json
      /records/200/existing_route_snapshots/1/dose      		Historical; current review incomplete
      H51-4B787DDFEF83CA3E242497DEdosing.json
      /records/200/existing_route_snapshots/1/interval      		Historical; current review incomplete
      H51-F8B09122F31C9519C23697E5dosing.json
      /records/200/existing_route_snapshots/1/duration      		Historical; current review incomplete
      H51-BC2C61670A615D5902445AAEdosing.json
      /records/200/existing_route_snapshots/1/administration      		Historical; current review incomplete
      H51-F7D32E692E912B74D1D161C7dosing.json
      /records/200/existing_route_snapshots/1/source_level      		Historical; current review incomplete
      H51-B600B59BA0DF2C942F37590Ddosing.json
      /records/200/existing_route_snapshots/1/notes      		Historical; current review incomplete
      H51-EB60DBF5916B88440D9646C6dosing.json
      /records/200/professional_sources/0      		Historical; current review incomplete
      H51-6C7BEFA82255ACD8199704CBdosing.json
      /records/200/professional_sources/0/label      		Historical; current review incomplete
      H51-608288924B8DD817AF05096Bdosing.json
      /records/200/professional_sources/0/url      		Historical; current review incomplete
      H51-D760C0EBDDF5DEF7955FEB64dosing.json
      /records/200/professional_sources/0/kind      		Historical; current review incomplete
      H51-0C53000B29209CCCE5200DB2dosing.json
      /records/200/professional_sources/1      		Historical; current review incomplete
      H51-BC91D4FA5F4B3510C6296593dosing.json
      /records/200/professional_sources/1/label      		Historical; current review incomplete
      H51-53B2BF6044E429DF597674C7dosing.json
      /records/200/professional_sources/1/url      		Historical; current review incomplete
      H51-3451E9EDF2C21A74FC5FAC9Edosing.json
      /records/200/professional_sources/1/kind      		Historical; current review incomplete
      H51-94E082E10E8BF0B4BB0B2647dosing.json
      /records/200/professional_sources/2      		Historical; current review incomplete
      H51-7FBF1294671B4D58AAAFC9F6dosing.json
      /records/200/professional_sources/2/label      		Historical; current review incomplete
      H51-242E528F3A7C2BFFC629E054dosing.json
      /records/200/professional_sources/2/url      		Historical; current review incomplete
      H51-24E23F7A442334EE846C1FBDdosing.json
      /records/200/professional_sources/2/kind      		Historical; current review incomplete
      H51-0C44567F39D19D1E7C1D1AFEdosing.json
      /records/200/professional_sources/3      		Historical; current review incomplete
      H51-086DFF249D815EA50F60D27Edosing.json
      /records/200/professional_sources/3/label      		Historical; current review incomplete
      H51-DAAA3C7A67A53C65B9F238B2dosing.json
      /records/200/professional_sources/3/url      		Historical; current review incomplete
      H51-D9CAC965674236D75860803Adosing.json
      /records/200/professional_sources/3/kind      		Historical; current review incomplete
      H51-8BFD25FF74962165FF61002Fdosing.json
      /records/200/clinical_review/locally_normalized      		Historical; current review incomplete
      H51-D188EBAEAF2921A0F78B99B8dosing.json
      /records/200/clinical_review/reviewed      		Historical; current review incomplete
      H51-F882C21AAC8AF314A3D7EBFBdosing.json
      /records/200/clinical_review/status      		Historical; current review incomplete
      H51-05234B26C4CD286F4B9D1372dosing.json
      /records/200/clinical_release_verification/audit_version      		Historical; current review incomplete
      H51-93D106C9DC5FCB93D0C3892Cdosing.json
      /records/200/clinical_release_verification/audited_on      		Historical; current review incomplete
      H51-A25B6D729C5DE02E956D514Cdosing.json
      /records/200/clinical_release_verification/level      		Historical; current review incomplete
      H51-9213DED6D97851B4A9122FA0dosing.json
      /records/200/clinical_release_verification/release_gate      		Historical; current review incomplete
      H51-367A3EF6A89F6AED3846D892dosing.json
      /records/200/clinical_release_verification/exact_current_label_candidate      		Historical; current review incomplete
      H51-E78DA0D07065E32A19BC42DBdosing.json
      /records/200/clinical_release_verification/selected_setid      		Historical; current review incomplete
      H51-411095757D36A4C296046134dosing.json
      /records/200/clinical_release_verification/selected_label_title      		Historical; current review incomplete
      H51-D0D9D46DF8E4F7D4A36153D9dosing.json
      /records/200/clinical_release_verification/numeric_support_ratio      		Historical; current review incomplete
      H51-C41EDE7A3947E159931F4EC0dosing.json
      /records/200/clinical_release_verification/reference_url_count      		Historical; current review incomplete
      H51-DC2774AE2D14710E02FEABFFdosing.json
      /records/200/clinical_release_verification/broken_reference_count      		Historical; current review incomplete
      H51-102743B1140E8017CE4A99C1dosing.json
      /records/200/clinical_release_verification/point_of_use_confirmation_required      		Historical; current review incomplete
      H51-4E199435D3F68EB129FD23DEdosing.json
      /records/200/clinical_release_verification/note      		Historical; current review incomplete
      H51-03A6D85E911105DBDC80BC49dosing.json
      /records/200/clinical_release_verification/dailymed_search_url      		Historical; current review incomplete
      H51-B095BA9B18129F5C5B450080first-look-v5.1.json
      /records/200/id      		Historical; current review incomplete
      H51-A1D6B0387FAF3B164B0508CFfirst-look-v5.1.json
      /records/200/generic_name      		Historical; current review incomplete
      H51-A8E3A46FC1ACB2AB387989C3first-look-v5.1.json
      /records/200/class      		Historical; current review incomplete
      H51-7DB177F3FB71C556FC0AE3FAfirst-look-v5.1.json
      /records/200/subclass      		Historical; current review incomplete
      H51-38F51EA27340B6EDEABDD886first-look-v5.1.json
      /records/200/primary_uses/0      		Historical; current review incomplete
      H51-BA0BBDEE3EF271E4B7B7DE13first-look-v5.1.json
      /records/200/primary_uses/1      		Historical; current review incomplete
      H51-2A29B99F35B5E2C60B709C50first-look-v5.1.json
      /records/200/primary_uses/2      		Historical; current review incomplete
      H51-28E40107F080D668113ED3F4first-look-v5.1.json
      /records/200/mechanism      		Historical; current review incomplete
      H51-DFC6AC6AB50A54CF62CDC7EBfirst-look-v5.1.json
      /records/200/mechanism_level      		Historical; current review incomplete
      H51-FC6E8BDEA528BB76FBF5D6ACfirst-look-v5.1.json
      /records/200/basic_dosing_orientation      		Historical; current review incomplete
      H51-46C3F9EBA7B45F4B2F4BB58Afirst-look-v5.1.json
      /records/200/administration_orientation      		Historical; current review incomplete
      H51-4FB3B45478CE882A20AA1785first-look-v5.1.json
      /records/200/renal_and_population_orientation      		Historical; current review incomplete
      H51-91CE61AA0B1245ADAB79C3ADfirst-look-v5.1.json
      /records/200/key_safety_orientation/0      		Historical; current review incomplete
      H51-9195D85AEA19E24C7FBAFA37first-look-v5.1.json
      /records/200/key_safety_orientation/1      		Historical; current review incomplete
      H51-EBDFA33ECC320ED4B0C328D4first-look-v5.1.json
      /records/200/key_safety_orientation/2      		Historical; current review incomplete
      H51-0C49E2FBA08EFCE36C44D69Afirst-look-v5.1.json
      /records/200/coverage_path      		Historical; current review incomplete
      H51-5D81BC8627EAB0CC4B4F2978first-look-v5.1.json
      /records/200/coverage_path_label      		Historical; current review incomplete
      H51-A96F001E66D277A629D83AFFfirst-look-v5.1.json
      /records/200/official_label_url      		Historical; current review incomplete
      H51-7298CD969A1E6318FAE5F55Cfirst-look-v5.1.json
      /records/200/legacy_title      		Historical; current review incomplete
      H51-8409B0A4DF8E45333C7A9A96first-look-v5.1.json
      /records/200/review_note      		Historical; current review incomplete
      H51-7F752E00A215538CA746C70Efirst-look-v5.1.json
      /records/200/search_text      		Historical; current review incomplete
      H51-1FDF265ACE05BAF44BD57418first-look-v5.1.json
      /records/200/official_search_url      		Historical; current review incomplete
      H51-717348EEBA6F8918DBCE17C1first-look-v5.1.json
      /records/200/official_access_mode      		Historical; current review incomplete
      H51-350B81D36CBDD4F77B17842Bfirst-look-v5.1.json
      /records/200/official_access_url      		Historical; current review incomplete
      H51-DD25FBF12B51F9966DD91867first-look-v5.1.json
      /records/200/official_search_query      		Historical; current review incomplete
      H51-C7DA6E32E9FB0D731F0147F7first-look-v5.1.json
      /records/200/official_access_reason      		Historical; current review incomplete
      H51-DEEC281C7160897030AC1AEFpreparation-assessments-v3.8.json
      /200/id      		Historical; current review incomplete
      H51-C203603D6433F83DDA8FEE51preparation-assessments-v3.8.json
      /200/name      		Historical; current review incomplete
      H51-82E70676F48A3B834B9C3C72preparation-assessments-v3.8.json
      /200/brands      		Historical; current review incomplete
      H51-B9D6B352917565E090983892preparation-assessments-v3.8.json
      /200/therapeutic_class      		Historical; current review incomplete
      H51-5FF3B9238B512D053941713Cpreparation-assessments-v3.8.json
      /200/review_version      		Historical; current review incomplete
      H51-673FE7B91E4BF69B3B071CB2preparation-assessments-v3.8.json
      /200/review_date      		Historical; current review incomplete
      H51-91D59E8D0E76E4BF5F875256preparation-assessments-v3.8.json
      /200/release_status      		Historical; current review incomplete
      H51-713506B5F9E5ADA6DA9985C9preparation-assessments-v3.8.json
      /200/market_status/status      		Historical; current review incomplete
      H51-158C382206177259E39E64E5preparation-assessments-v3.8.json
      /200/market_status/basis      		Historical; current review incomplete
      H51-B552748F5D134F26497B388Epreparation-assessments-v3.8.json
      /200/ten_point_assessment/exact_formulation      		Historical; current review incomplete
      H51-5A52488F05501AF4E032CD94preparation-assessments-v3.8.json
      /200/ten_point_assessment/reconstitution_concentration      		Historical; current review incomplete
      H51-212A06400CB87D4FDF5A50AFpreparation-assessments-v3.8.json
      /200/ten_point_assessment/maximum_or_recommended_final_concentration      		Historical; current review incomplete
      H51-6F7E9B2B14504B518E03F8EBpreparation-assessments-v3.8.json
      /200/ten_point_assessment/appropriate_standardized_containers      		Historical; current review incomplete
      H51-C6D1A8DA64B502E77AEFA365preparation-assessments-v3.8.json
      /200/ten_point_assessment/adult_dosing_range      		Historical; current review incomplete
      H51-6943411CCA68506EC47B9767preparation-assessments-v3.8.json
      /200/ten_point_assessment/pediatric_dosing_range      		Historical; current review incomplete
      H51-D31DD69873AE432C57BC4467preparation-assessments-v3.8.json
      /200/ten_point_assessment/neonatal_dosing_range      		Historical; current review incomplete
      H51-EB7D7C78F0EB34A24369C904preparation-assessments-v3.8.json
      /200/ten_point_assessment/infusion_time      		Historical; current review incomplete
      H51-DD37F61088C9978DC02CE374preparation-assessments-v3.8.json
      /200/ten_point_assessment/fluid_restriction_alternatives      		Historical; current review incomplete
      H51-9F09A200D4AA5A2E01FF9B9Epreparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/setid      		Historical; current review incomplete
      H51-2C2F91E89FA8D8372C3996DBpreparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/title      		Historical; current review incomplete
      H51-D0AF97BD5CAE24EBE289A356preparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/published_date      		Historical; current review incomplete
      H51-59793AAB57F33DF04C1C4759preparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/manufacturer      		Historical; current review incomplete
      H51-4D6A670B5A5D7F73B959EBBBpreparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/match_confidence      		Historical; current review incomplete
      H51-14F4A2E521D45836BFDE4CC2preparation-assessments-v3.8.json
      /200/ten_point_assessment/current_manufacturer_labeling/url      		Historical; current review incomplete
      H51-E97193D74B3C197E0DBBD707preparation-assessments-v3.8.json
      /200/field_provenance/exact_formulation/primary      		Historical; current review incomplete
      H51-4E807D8F7D3B33E2D793532Apreparation-assessments-v3.8.json
      /200/field_provenance/reconstitution_concentration/primary      		Historical; current review incomplete
      H51-BB28691AF8F07788E30FEF40preparation-assessments-v3.8.json
      /200/field_provenance/maximum_or_recommended_final_concentration/primary      		Historical; current review incomplete
      H51-E171D67C3D7298DB50B2E098preparation-assessments-v3.8.json
      /200/field_provenance/appropriate_standardized_containers/primary      		Historical; current review incomplete
      H51-26FF3EE771068D41C326A4C9preparation-assessments-v3.8.json
      /200/field_provenance/adult_dosing_range/primary      		Historical; current review incomplete
      H51-DA3035E4814CCEB310EDA68Cpreparation-assessments-v3.8.json
      /200/field_provenance/pediatric_dosing_range/primary      		Historical; current review incomplete
      H51-9D66A2A9ED287F40C209AC44preparation-assessments-v3.8.json
      /200/field_provenance/neonatal_dosing_range/primary      		Historical; current review incomplete
      H51-1A405702F2A7F445AADD084Fpreparation-assessments-v3.8.json
      /200/field_provenance/infusion_time/primary      		Historical; current review incomplete
      H51-538E73A861332F4DD1396FEDpreparation-assessments-v3.8.json
      /200/field_provenance/fluid_restriction_alternatives/primary      		Historical; current review incomplete
      H51-7A93B4AF8E6EE5E0749C7462preparation-assessments-v3.8.json
      /200/field_provenance/current_manufacturer_labeling/primary      		Historical; current review incomplete
      H51-1C5BF4648170E29C17D23D37preparation-assessments-v3.8.json
      /200/population_applicability/adult/applicability      		Historical; current review incomplete
      H51-DB758937436487AEB8D62C7Dpreparation-assessments-v3.8.json
      /200/population_applicability/adult/guide_generation_allowed      		Historical; current review incomplete
      H51-85F12B5A5342BE99314342E3preparation-assessments-v3.8.json
      /200/population_applicability/pediatric/applicability      		Historical; current review incomplete
      H51-DE267E83D7364E0B9937D7FApreparation-assessments-v3.8.json
      /200/population_applicability/pediatric/guide_generation_allowed      		Historical; current review incomplete
      H51-6DF2C155FC2ABF8EC5E99FA5preparation-assessments-v3.8.json
      /200/population_applicability/neonatal/applicability      		Historical; current review incomplete
      H51-5BA0FF8A8044FE43E109EBA5preparation-assessments-v3.8.json
      /200/population_applicability/neonatal/guide_generation_allowed      		Historical; current review incomplete
      H51-C9390843A107B69E7D6614B2preparation-assessments-v3.8.json
      /200/route_presence/structured_dilution      		Historical; current review incomplete
      H51-9B7E46042133C1CBE3463E37preparation-assessments-v3.8.json
      /200/route_presence/iv_push      		Historical; current review incomplete
      H51-997F222CB875CFC3985B0FADpreparation-assessments-v3.8.json
      /200/route_presence/continuous_infusion      		Historical; current review incomplete
      H51-2E645A21B287F676AA2CF1A0preparation-assessments-v3.8.json
      /200/route_presence/pediatric_source      		Historical; current review incomplete
      H51-B82FEB489D61A9C3A8B979A7preparation-assessments-v3.8.json
      /200/route_presence/neonatal_source      		Historical; current review incomplete
      H51-343EA203CFD6F75F72172772preparation-assessments-v3.8.json
      /200/legacy_reference/status      		Historical; current review incomplete
      H51-AFDEDF348F30DE28336CA4C1preparation-assessments-v3.8.json
      /200/label_resolution/status      		Historical; current review incomplete
      H51-B9F792D9953F80B010E723DApreparation-assessments-v3.8.json
      /200/source_files/0      		Historical; current review incomplete
      H51-F444C9C5F45450E3C5A56C11preparation-assessments-v3.8.json
      /200/source_files/1      		Historical; current review incomplete
      H51-BE0FFC1D3D14C4E8878C064Dpreparation-assessments-v3.8.json
      /200/source_files/2      		Historical; current review incomplete
      H51-82789C89FA13F192F35D929Epreparation-assessments-v3.8.json
      /200/clinical_release_note      		Historical; current review incomplete

      Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)

      All medicationsReturn to medication headingApplication top